Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy

STATEMENT OF NEED

Hereditary amyloid transthyretin (ATTR) amyloidosis is a progressively debilitating disease caused by the buildup of variant transthyretin proteins in amyloid deposits in the heart, nerves, and digestive system. Symptoms of ATTR amyloidosis with cardiomyopathy (ATTR-CM) overlap with those of other more commonly recognized cardiac diseases, leading to misdiagnosis. As ATTR is now a treatable disease due to recent advances, it is crucial for members of the interdisciplinary care team to remain up to date on genetic testing and diagnostic modalities to improve early identification for early diagnosis and optimal treatment selection (American Heart Association, 2024; Nativi-Nicolau et al, 2021). This activity, presented by Mathew Maurer, MD, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will explore strategies for increasing detection and improving outcomes in patients with hereditary ATTR-CM.

TARGET AUDIENCE

Cardiologists, geneticists, primary care physicians, advanced practitioners, nurses, pharmacists, and other healthcare providers involved in the treatment of patients with cardiomyopathy due to transthyretin amyloidosis (ATTR-CM).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Evaluate clinical features and diagnostic tests that can enable the timely identification of hereditary ATTR and ATTR-CM
• Assess the safety and efficacy of current and emerging therapies for hereditary ATTR-CM
• Appraise treatment selection considerations for individual patients with hereditary ATTR-CM or mixed phenotype

 REGISTRATION

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 8/12/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development 

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.5 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour. 

Continuing Pharmacy Education

i3 Health has approved this knowledge-based activity for 1.0 ACPE CE hour. The Universal Activity Number for this activity is JA0008128-0000-25-029-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion. 

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

Mathew Maurer, MD, discloses that he has served on an advisory board or panel for Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer; and that he has received grants/research support from Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer. 

The i3 Health planners, reviewers, and managers have nothing to disclose.

i3 Health has mitigated all relevant financial relationships.